DAZAP2

DAZAP2 is a small multifunctional scaffold/adaptor protein that tunes the output of several signaling and transcriptional pathways, predominantly by modulating the activity, stability, or nuclear access of partner factors (PMID:19304756, PMID:33591310). In Wnt signaling it binds TCF/LEF transcription factors at a region adjacent to the TCF-4 HMG box and adjusts TCF-4 affinity for DNA, with its loss reducing β-catenin-dependent transcription and altering Wnt target gene expression (PMID:19304756). In IL-25 (IL-17E) signaling DAZAP2 binds the IL-25 receptor IL-17RB and acts as an inhibitory adaptor; IL-25 stimulation recruits TRAF4, which engages the E3 ligase SMURF2 to drive DAZAP2 proteasomal degradation, relieving the block on ACT1/IL-25R coupling and permitting downstream signaling (PMID:25681341, PMID:22070932). In the DNA damage response, DAZAP2 normally promotes SIAH1-dependent polyubiquitination and degradation of HIPK2; HIPK2 in turn site-specifically phosphorylates DAZAP2, terminating this activity and triggering DAZAP2 relocalization to the nucleus where it interacts with p53 and co-occupies p53 response elements to shape a defined subset of p53 target genes and cell fate, such that DAZAP2 loss potentiates chemosensitivity (PMID:33591310). DAZAP2 also acts in developmental and germline contexts—maintaining germ granules by binding Bucky ball and counteracting Dynein in zebrafish primordial germ cells (PMID:26119733), and specifying posterior neural identity downstream of FGF receptor activation independently of Wnt and Cdx in Xenopus (PMID:19555680)—and functions as a pan-coronavirus restriction factor that blocks virion membrane fusion and suppresses viral RNA replication, an effect attributed to indirect regulation of host gene expression from its nuclear compartment (PMID:40833112). Its expression is itself controlled by p38/MAPK/CREB-driven transcription that is silenced by promoter CpG hypermethylation in multiple myeloma (PMID:31034872).

1. 2004 Low

   Established the baseline subcellular distribution of DAZAP2, the first step toward asking where it acts.

   Evidence Confocal microscopy of EGFP-DAZAP2 fusion in transfected COS7 cells

   PMID:15629043

   Open questions at the time

   • Single localization experiment with no functional consequence linked
   • Overexpressed fusion in a heterologous cell line may not reflect endogenous distribution
   • Does not address the nuclear pools later implicated in p53 and antiviral functions
2. 2009 High

   Defined the first transcriptional role for DAZAP2 by showing it binds TCF/LEF factors and tunes Wnt/β-catenin target gene output, answering whether DAZAP2 directly influences a named transcription factor.

   Evidence Co-IP, deletion mapping, ChIP, and siRNA knockdown with Wnt reporter assays

   PMID:19304756

   Open questions at the time

   • Mechanism by which DAZAP2 alters TCF-4 DNA affinity at the molecular level is undefined
   • Does not establish whether the effect is direct on DNA binding or via additional cofactors
3. 2009 High

   Placed DAZAP2 in vertebrate axial patterning, showing it acts downstream of FGF receptor signaling to specify posterior neural identity and distinguishing this from Wnt and Cdx inputs.

   Evidence Morpholino knockdown, mRNA overexpression, in situ hybridization, and pathway epistasis in Xenopus embryos

   PMID:19555680

   Open questions at the time

   • Molecular effector linking DAZAP2 to hoxb9 induction is unknown
   • Relationship between this developmental role and its biochemical activities is unresolved
4. 2011 High

   Identified DAZAP2 as a direct IL-17RB-binding adaptor and mapped the interaction and its SMURF2-driven degradation, answering how DAZAP2 engages the IL-25 receptor.

   Evidence Yeast two-hybrid, co-IP, domain/point mutagenesis, confocal microscopy, and proteasome inhibitor assays

   PMID:22070932

   Open questions at the time

   • Functional consequence of binding for IL-25 signaling not yet established in this study
   • Trigger for SMURF2-mediated degradation not defined
5. 2015 High

   Resolved DAZAP2's role as an inhibitory brake on IL-25 signaling that is released by TRAF4/SMURF2-mediated degradation, establishing a regulated derepression switch in vivo.

   Evidence Traf4-/- knockout mice, co-IP, siRNA, and in vivo IL-25 airway inflammation challenge

   PMID:22070932 PMID:25681341

   Open questions at the time

   • How DAZAP2 sterically or biochemically blocks ACT1/IL-25R coupling is not detailed
   • Whether this brake operates in other IL-17 family receptors is untested
6. 2015 High

   Extended DAZAP2 function to germline development, showing it maintains germ granules by binding Bucky ball and antagonizing Dynein, the first cytoskeletal/RNP-related role.

   Evidence Zebrafish genetic mutants, co-IP, epistasis with Tdrd7 and dynein, and confocal colocalization

   PMID:26119733

   Open questions at the time

   • Mechanism of Dynein antagonism is not defined
   • Whether mammalian DAZAP2 retains a germ-granule function is unaddressed
7. 2019 Medium

   Defined how DAZAP2 expression is controlled, showing p38/MAPK/CREB drives its transcription and that promoter CpG hypermethylation silences it in multiple myeloma.

   Evidence Bisulfite sequencing, luciferase promoter assays, ChIP, demethylation (5-aza), and p38 inhibition

   PMID:31034872

   Open questions at the time

   • Single-lab study not independently replicated
   • Functional consequence of DAZAP2 silencing for myeloma biology is not established
8. 2021 High

   Established a phosphorylation-gated switch in which DAZAP2 controls HIPK2 stability until HIPK2 phosphorylates it, relocalizing DAZAP2 to the nucleus to shape p53 target gene output and chemosensitivity.

   Evidence siRNA, CRISPR KO, co-IP, ubiquitination and phosphorylation assays, ChIP, site-specific mutagenesis, and mouse xenografts

   PMID:33591310

   Open questions at the time

   • The basis for selectivity of which p53 response elements are co-occupied is unclear
   • How nuclear DAZAP2 mechanistically biases p53 output is undefined
9. 2025 High

   Identified DAZAP2 as a pan-coronavirus restriction factor acting at both viral entry/fusion and RNA replication steps, defining an antiviral function distinct from its other roles.

   Evidence Genome-wide CRISPR KO screen, DAZAP2 KO mice, primary human airway epithelial infection, and entry/fusion vs. replication assays

   PMID:40833112

   Open questions at the time

   • The proposed indirect mechanism via host gene expression is not molecularly resolved
   • How a nuclear protein blocks membrane fusion is unexplained
10. 2026 Medium

    Connected DAZAP2 to BMP/SMAD signaling, showing miR-378a suppression of DAZAP2 enhances nuclear p-SMAD1/5/9 and osteogenic differentiation.

    Evidence miRNA overexpression, target identification, 3'UTR reporter, DAZAP2 rescue, and Western blot for nuclear p-SMAD

    PMID:42185189

    Open questions at the time

    • Single-lab study with implied (not shown) reporter validation
    • Direct molecular link between DAZAP2 and SMAD nuclear translocation is not defined

• A unifying biochemical activity that explains how one small adaptor influences Wnt, IL-25, p53, BMP, developmental patterning, and antiviral pathways remains undefined.
• No structural model or defined domain-level activity ties the disparate functions together
• Whether a common partner-binding mode underlies all roles is unknown
• The relationship between cytoplasmic and nuclear pools across contexts is unresolved